Wir sind mit live! Mehr erfahren
HRTS-Symbol

Tema ETF Trust Tema Heart & Health ETF

36,90 USD
-0,33
0,89 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
1 Tag
-0,89 %
5 Tage
1,91 %
1 Monat
2,07 %
3 Monate
1,04 %
6 Monate
7,93 %
Seit Jahresbeginn
4,33 %
1 Jahr
14,74 %
5 Jahre
38,57 %
10 Jahre
38,57 %

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 100 %
Neutral 0 %
Negativ 0 %
Positiv
Zacks Investment Research
vor 15 Tagen
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
LLY and Novo face off at EASD as new data fuels the GLP-1 market, while ETFs offer diversified exposure to weight loss drug growth.
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to Win
Positiv
Zacks Investment Research
vor 3 Monaten
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage
Neutral
Business Wire
vor 4 Monaten
Tema ETFs Exceeds $5bn in AUM After Three Years
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, has surpassed $5 billion in assets under management (AUM) three years since listing its first product with $5 million.1 Tema has grown AUM by more than $3 billion in the first five months of 2026,2 underscoring strong momentum and growing adoption from financial advisors and professional investors.
Tema ETFs Exceeds $5bn in AUM After Three Years
Positiv
Zacks Investment Research
vor 4 Monaten
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Inside the GLP-1 Boom: ETF Picks for the Obesity Drug Market
Positiv
Zacks Investment Research
vor 5 Monaten
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.
GLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to Gain
Neutral
Business Wire
vor 8 Monaten
Tema Appoints ETF Industry Leader Steve Munroe as President
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), a leader in institutional-quality and actively managed exchange-traded funds, today announced the appointment of Steve Munroe as President. In this role, Mr. Munroe will partner with Tema Founder and CEO Maurits Pot and the firm's leadership team to accelerate the company's next phase of growth. He will oversee branding, marketing, distribution, and product strategy as Tema continues to gain momentum—raising more than $1 billion in net new assets o.
Tema Appoints ETF Industry Leader Steve Munroe as President
Positiv
ETF Trends
vor 9 Monaten
New Year, New Strategy: Navigating Weight Loss ETFs
With the start of 2026, the annual focus on weight loss resolutions presents a timely opportunity for financial advisors to discuss the investment potential of GLP-1 agonists with their clients. This class of drugs has fundamentally altered the healthcare sector's growth projections.
New Year, New Strategy: Navigating Weight Loss ETFs
Neutral
Business Wire
letztes Jahr
Tema Surpasses $1bn AUM Two Years After Launch, Strengthens Team With Key Growth Hires
NEW YORK--(BUSINESS WIRE)--Tema ETFs (“Tema”), the New York-based provider of innovative exchange traded funds (ETFs), has surpassed $1 billion in assets under management (AUM) in just two years since launch, achieved with less than $5m of initial seed AUM. Tema also announces the hiring of Devan O'Dowd as Head of Distribution and Ceri Llewelyn as Director of Marketing. Three highlights to note: Institutional Adoption: Tema estimates that over 90% of current AUM originates from Registered Inves.
Tema Surpasses $1bn AUM Two Years After Launch, Strengthens Team With Key Growth Hires
Positiv
ETF Trends
letztes Jahr
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
For many of us, a new year often means a new chance to start fresh in our battle with weight. Thanks to interesting ETF product development, especially in the past year, it could also mean a chance to consider the investment opportunity in weight loss as a theme.
New Year's Resolutions: Lose Weight & Allocate to GLP-1 ETFs
Positiv
ETF Trends
letztes Jahr
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
2024 was an amazing year for investment performance, with the broad market S&P 500 TR Index up over 28%. There were also some serious ETF milestones achieved this year.
Disruptive Theme of the Week: 2024's Top Investment Themes & Trends
Kursdiagramme mit Lightweight Charts™ umgesetzt